As Eli Lilly announced in a statement Symbyax is indicated for acute treatment of adult patients with major depressive disorder who have not responded to two separate trials of different antidepressants of adequate dose and duration in their current episode.

 

Treatment-resistant depression is generally defined as the continuation of depression symptoms despite treatment with at least three or four different medications.

 

It is estimated that up to 35 percent of patients with depression - or approximately two percent of the general population - fail to achieve an adequate response to two respective antidepressant drug therapy attempts.

 

Symbyax may induce orthostatic hypotension associated with dizziness, tachycardia, bradycardia, and in some patients, syncope, especially during the initial dose-titration period. Particular caution should be used in patients with known cardiovascular disease, cerebrovascular diseases, or those predisposed to hypotension.

 

Symbyax should be used cautiously in patients with a history of seizures or with conditions that lower the seizure threshold.